Given that ovarian cancer patients enrolled on phase 1 trials usually have platinum‐resistant and heavily pretreated disease, with a poor prognosis, researchers undertook this retrospective single‐institution series with 132 patients to evaluate prognostic factors as well as survival among women suffering from recurrent ovarian cancer who were treated on phase 1 clinical trials. They reported an overall response rate of 14.7%. A raised cancer antigen 125 level and albumin < 3.5 g/dL were identified as the independent risk factors predictive of shorter survival. Longer survival was predicted by a BMI > 25 kg/m2. The median overall survival was estimated to be 11.3 months in patients with heavily pretreated ovarian cancer who were treated on phase 1 clinical trials. For cases of heavily pretreated ovarian cancer with a preserved performance status, a reasonable treatment choice is phase 1 clinical trials, when available.
Read the full article on Cancer.